Table 3 Trial medication during induction therapy, high-dose melphalan and lenalidomide maintenance therapy.

From: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

Medication mean (interquartile ranges)

S1

S2

S3

p

Induction therapy

  Bortezomib (cumulative mg/m2)

15.1 (14.7–15.7)

15.0 (15.1–15.7)

14.8 (14.5–15.7)

0.56

  Doxorubicine (cumulative mg/m2)

106.4 (105.7–109.0)

107.5 (106.7–109.6)

105.9 (104.9–108.7)

0.13

  Cyclophosphamide (cumulative mg/m2)

2564.2 (2619.6–2704.9)

2600.8 (2608.7–2700.0)

2574.8 (2647.3–2702.3)

0.52

  Dexamethasone (mg/cycle)

277.4 (240–320)

285.2 (240–320)

270.5 (240–320)

<0.001

MEL200/ASCT

  First ASCT (melphalan, mg/m2/cycle)

196.4 (200.0–200.0)

197.8 (200.0–200.0)

206.3 (200.0–200.0)

0.05

  Second ASCT (melphalan, mg/m2/cycle)

195.9 (200.0–200.0)

195.5 (200.0–200.0)

178.0 (183.0–200.0)

<0.001

Maintenance therapy

  Lenalidomide (mg/day)

11.5 (10.0–15.0)

10.6 (10.0–15.0)

10.6 (10.0–15.0)

<0.001

  1. Applied doses of trial medication with respect to the three age groups ≤60 years (S1), 61–65 years (S2) and 66–70 years (S3).
  2. Bold p values are statistically significant.
  3. MEL200 melphalan 200 mg/m2; ASCT autologous blood stem cell transplantation.
Back to article page